WO2002072605A3 - Expression technology for proteins containing a hybrid isotype antibody moiety - Google Patents

Expression technology for proteins containing a hybrid isotype antibody moiety Download PDF

Info

Publication number
WO2002072605A3
WO2002072605A3 PCT/US2002/007011 US0207011W WO02072605A3 WO 2002072605 A3 WO2002072605 A3 WO 2002072605A3 US 0207011 W US0207011 W US 0207011W WO 02072605 A3 WO02072605 A3 WO 02072605A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antibody moiety
proteins containing
expression technology
isotype antibody
Prior art date
Application number
PCT/US2002/007011
Other languages
French (fr)
Other versions
WO2002072605A2 (en
Inventor
Stephen D Gillies
Jeffrey Way
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Priority to CA2440221A priority Critical patent/CA2440221C/en
Priority to DK02717581.9T priority patent/DK1366067T3/en
Priority to BR0207854-6A priority patent/BR0207854A/en
Priority to HU0303428A priority patent/HUP0303428A2/en
Priority to KR1020037011719A priority patent/KR100900176B1/en
Priority to EP02717581A priority patent/EP1366067B1/en
Priority to MXPA03008031A priority patent/MXPA03008031A/en
Priority to JP2002571518A priority patent/JP4234438B2/en
Priority to ES02717581T priority patent/ES2393733T3/en
Priority to AU2002248571A priority patent/AU2002248571B2/en
Publication of WO2002072605A2 publication Critical patent/WO2002072605A2/en
Publication of WO2002072605A3 publication Critical patent/WO2002072605A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
PCT/US2002/007011 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety WO2002072605A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2440221A CA2440221C (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety
DK02717581.9T DK1366067T3 (en) 2001-03-07 2002-03-07 EXPRESSION TECHNOLOGY FOR PROTEINS CONTAINING A HYBRID ISOTYPE ANTIBODY UNIT
BR0207854-6A BR0207854A (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety
HU0303428A HUP0303428A2 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety
KR1020037011719A KR100900176B1 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety
EP02717581A EP1366067B1 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety
MXPA03008031A MXPA03008031A (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety.
JP2002571518A JP4234438B2 (en) 2001-03-07 2002-03-07 Expression technology of protein containing hybrid isotype antibody part
ES02717581T ES2393733T3 (en) 2001-03-07 2002-03-07 Expression technology for proteins that contain a hybrid isotype antibody fraction
AU2002248571A AU2002248571B2 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27409601P 2001-03-07 2001-03-07
US60/274,096 2001-03-07

Publications (2)

Publication Number Publication Date
WO2002072605A2 WO2002072605A2 (en) 2002-09-19
WO2002072605A3 true WO2002072605A3 (en) 2002-11-14

Family

ID=23046749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007011 WO2002072605A2 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety

Country Status (17)

Country Link
US (2) US7148321B2 (en)
EP (1) EP1366067B1 (en)
JP (1) JP4234438B2 (en)
KR (2) KR100900176B1 (en)
CN (1) CN1330664C (en)
AU (1) AU2002248571B2 (en)
BR (1) BR0207854A (en)
CA (1) CA2440221C (en)
DK (1) DK1366067T3 (en)
ES (1) ES2393733T3 (en)
HU (1) HUP0303428A2 (en)
MX (1) MXPA03008031A (en)
PL (1) PL206701B1 (en)
PT (1) PT1366067E (en)
RU (1) RU2003129528A (en)
WO (1) WO2002072605A2 (en)
ZA (1) ZA200307792B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (en) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor
DK1187852T3 (en) * 1999-05-19 2007-11-26 Merck Patent Gmbh Expression and export of interferon alpha proteins as Fc fusion proteins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CN1270775C (en) * 2000-06-29 2006-08-23 默克专利有限公司 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enbancing agents
DE10045591A1 (en) 2000-09-15 2002-04-04 Klaus Pfizenmaier Site-specific, antibody-mediated activation of proapoptotic cytokines - AMAIZe (Antibody-Mediated Apoptosis Inducing Cytokines)
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100900176B1 (en) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
CA2469151C (en) * 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2008502317A (en) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング IL-7 fusion protein
KR20060124656A (en) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2570990C (en) * 2004-07-16 2014-01-21 Micromet Ag Expression-enhanced polypeptides
JP4937132B2 (en) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング IL-7 variants with reduced immunogenicity
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2460517T3 (en) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reduction of b cells by using cd37 specific binding and cd20 specific binding molecules
BRPI0614850A2 (en) * 2005-08-19 2011-04-19 Centocor Inc proteolysis resistant antibody preparations
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2627444A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EA016429B1 (en) 2005-12-30 2012-04-30 Мерк Патент Гмбх Anti-cd19 antibodies with reduced immunogenicity
SI1966238T1 (en) * 2005-12-30 2012-08-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
AU2006332216A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6Ralpha to gp130
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AR059193A1 (en) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag MODULATION OF THE ACTIVITY OF MDL-1 FOR THE TREATMENT OF INFLAMMATORY DISEASES
BRPI0710048A2 (en) * 2006-03-30 2011-08-02 Lg Electronics Inc method and apparatus for decoding / encoding a video signal
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (en) 2006-03-31 2021-10-15 中外制药株式会社 Method for regulating antibody hemodynamics
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
JP2009542592A (en) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Compositions and methods for enhancing the effectiveness of an IL-2-mediated immune response
EP2142256B1 (en) * 2007-03-30 2015-10-14 Baker Medical Research Institute Treatment of obesity
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
JP5168538B2 (en) * 2007-05-24 2013-03-21 アボットジャパン株式会社 Antibody-antibody conjugates and application to diagnostic antibodies
US8680237B2 (en) * 2007-06-01 2014-03-25 Gliknik Inc. Immunoglobulin constant region FC receptor binding agents
AU2013263716B2 (en) * 2007-06-01 2016-01-07 Gliknik Inc Immunoglobulin constant region FC receptor binding agents
EP2172550B1 (en) * 2007-06-29 2014-08-06 Daiichi Sankyo Company, Limited C-TERMINAL-alpha-AMIDATED RECOMBINANT ENZYME DERIVATIVE
AU2008287195A1 (en) * 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
EP2197911A2 (en) 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
TWI464262B (en) 2007-09-26 2014-12-11 中外製藥股份有限公司 Antibody constant region mutant
KR101658247B1 (en) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 Antibody targeting through a modular recognition domain
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
DK2132228T3 (en) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37 immunotherapeutic agent and combination with its bifunctional chemotherapeutic agent
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
MA33405B1 (en) 2009-05-15 2012-07-03 Chugai Pharmaceutical Co Ltd Antibodies against axl
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
KR101965585B1 (en) * 2009-10-29 2019-04-04 얀센 바이오테크 인코포레이티드 Antibody glycosylation variants
LT3460056T (en) * 2009-11-02 2020-12-28 University Of Washington Therapeutic nuclease compositions and methods
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN101870735B (en) * 2010-06-02 2013-06-12 北京精益泰翔技术发展有限公司 High-glycosylation erythropoietin immune fusion protein
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
MX347343B (en) 2010-07-28 2017-04-21 Gliknik Inc Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions.
KR101333958B1 (en) 2010-10-20 2013-11-27 주식회사 한독 Human Interleukin-1 receptor antagonist-hybrid Fc fusion protein
EP3144320B9 (en) * 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
IL300276A (en) 2011-04-29 2023-04-01 Univ Washington Therapeutic nuclease compositions and methods
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
MX2014002289A (en) * 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Tandem fc bispecific antibodies.
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CN103974977A (en) * 2011-09-26 2014-08-06 Jn生物科学有限责任公司 Hybrid constant regions
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2842969B1 (en) 2012-04-23 2018-03-14 NRL Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
EA038918B1 (en) 2013-03-15 2021-11-09 Зинджения, Инк. Peptide binding an epidermal growth factor receptor, multispecific complexes comprising peptide and antibodies and use thereof
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
EP4130044A1 (en) 2013-09-13 2023-02-08 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
ES2759252T3 (en) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Nuclease-albumin fusions and therapeutic methods
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
CA2934979A1 (en) 2014-02-10 2015-08-13 Merck Patent Gmbh Targeted tgf.beta. inhibition
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6851200B2 (en) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル Multimeric Fc protein
BR112016022841B1 (en) * 2014-04-03 2023-09-26 Igm Biosciences, Inc IGM, IGA, IGG/IGM OR IGG/IGA ANTIBODY COMPRISING A MODIFIED CHAIN
BR112016023500A2 (en) 2014-04-10 2017-10-17 Seattle Childrens Hospital Dba Seattle Childrens Res Inst method and compositions for cellular immunotherapy
EP3148573A4 (en) * 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof
KR102130600B1 (en) 2014-07-03 2020-07-08 베이진 엘티디 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
WO2016014688A2 (en) 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
JP6909153B2 (en) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド Anti-PD-L1 antibody
HUE051414T2 (en) 2014-08-11 2021-03-01 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
HUE050596T2 (en) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
MX2017006323A (en) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions.
US10894089B2 (en) 2015-02-17 2021-01-19 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue conjugate
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3878857A1 (en) 2015-04-22 2021-09-15 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
US10280449B2 (en) * 2015-06-29 2019-05-07 The Regents Of The University Of California Methods of producing nucleic acid libraries and compositions and kits for practicing same
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
UA126278C2 (en) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Cd3 binding polypeptides
JP7065766B2 (en) 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド Bonded molecule with modified J chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
WO2017096361A1 (en) 2015-12-04 2017-06-08 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017293423B2 (en) 2016-07-05 2023-05-25 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
EP3497130B1 (en) 2016-08-12 2021-10-27 Merck Patent GmbH Combination therapy for cancer
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018079702A1 (en) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ Lactoferrin/albumin fusion protein and production method therefor
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018107079A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
KR20190093186A (en) 2016-12-09 2019-08-08 글리크닉 인코포레이티드 How to treat inflammatory disorders by multivalent Fc compounds
EP3551197B1 (en) 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
KR102413686B1 (en) * 2017-07-07 2022-06-28 한미약품 주식회사 Novel therapeutic enzyme fusion protein and use thereof
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
SG11202007927WA (en) 2018-03-09 2020-09-29 Agenus Inc Anti-cd73 antibodies and methods of use thereof
CN116327926A (en) 2018-03-15 2023-06-27 中外制药株式会社 Anti-dengue virus antibodies with cross-reactivity to Zika virus and methods of use
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
CA3117429A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
EP3873612A2 (en) 2018-11-01 2021-09-08 Merck Patent GmbH Methods of administering anti-tim-3 antibodies
KR102371173B1 (en) 2018-12-21 2022-03-04 오제 이뮈노테라프틱스 Humanized Anti-Human-PD-1 Antibody
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US11512122B2 (en) 2019-05-17 2022-11-29 Xencor, Inc. IL-7-FC-fusion proteins
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
CA3224182A1 (en) * 2021-06-17 2022-12-22 Fapon Biotech Inc. Chimeric immunoglobulin
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
WO2023076927A1 (en) * 2021-10-27 2023-05-04 Anwita Biosciences, Inc. Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
CN114835810B (en) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 anti-PD-1 nano antibody and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004329A1 (en) * 1989-09-20 1991-04-04 Abbott Laboratories Method of producing fusion proteins
WO1991013166A1 (en) * 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
WO1999043713A1 (en) * 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81664A (en) * 1868-09-01 Island
US166877A (en) * 1875-08-17 Improvement in electric lights
US147311A (en) * 1874-02-10 Improvement in electric telegraphs
US12789A (en) * 1855-05-01 Office
US192222A (en) * 1877-06-19 Improvement in watches
US193570A (en) * 1877-07-24 Improvement in washing-boards
US105294A (en) * 1870-07-12 Erasmus w
US3529A (en) * 1844-04-10 yvolfe
US49227A (en) * 1865-08-08 Improvement in construction of railway trains and cars
US44423A (en) * 1864-09-27 Improved screw for music-stools
US53539A (en) * 1866-03-27 Improvement in revolving fire-arms
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3712985A1 (en) 1987-04-16 1988-11-03 Hoechst Ag BIFUNCTIONAL PROTEINS
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (en) 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (en) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド Targeted multifunctional protein
ATE122238T1 (en) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc BIFUNCTIONAL ANTIBODY CONSTRUCTIONS AND METHOD FOR SELECTIVE KILLING OF CELLS.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ES2058199T3 (en) 1987-09-23 1994-11-01 Bristol Myers Squibb Co ANTIBODY HETEROCONJUGATES FOR THE ELIMINATION OF HIV-INFECTED CELLS.
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (en) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro SPECIFIC MONOCLONAL ANTIBODY FOR A SEQUENCE OF FIBRONETIN EXPRESSED IN TRANSFORMED HYBRID CELLS ACCORDING TO SUCH ANTIBODY AND USE OF THE MONOCLONAL ANTIBODY FOR THE DIAGNOSIS OF TUMORS
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0406857B1 (en) 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
WO1991005867A1 (en) 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
DE69034249T2 (en) 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for the cytotoxic lymphocyte maturation factor
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0601043B1 (en) 1991-08-30 1998-11-25 Fred Hutchinson Cancer Research Center Hybrid cytokines
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5277375A (en) * 1991-12-04 1994-01-11 The Procter & Gamble Company Spindle for use with compressed core wound paper products
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
DK0633929T3 (en) 1992-04-01 2004-06-28 Univ Rockefeller Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU666388B2 (en) * 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
DE69332485T2 (en) 1992-08-11 2003-11-13 Harvard College Immunomodulatory peptides
DE4228839A1 (en) 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
WO1994009820A1 (en) 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
EP0695347B1 (en) * 1993-04-20 2007-08-01 Hipler Partners, Llp Methods and materials for treatment of individuals infected with intracellular infectious agents
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
EP0744953A4 (en) 1993-04-29 1998-05-06 Abbott Lab Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5609876A (en) * 1993-08-09 1997-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide vaccines and associated methods for protection against feline leukemia virus
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
MX9605109A (en) 1994-04-26 1997-08-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis.
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
CU22615A1 (en) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
JP3429578B2 (en) * 1994-10-31 2003-07-22 オリンパス光学工業株式会社 Small rear focus zoom lens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
DE69632949T2 (en) 1995-03-10 2005-07-28 Genentech, Inc., South San Francisco THE ACTIVATION OF RECEPTORS BY GAS6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
KR19990028388A (en) 1995-06-30 1999-04-15 피터 지. 스트링거 How to Treat Diabetes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CN1136197C (en) 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 Novel pyridajinone derivatives
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ES2176574T3 (en) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY.
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE225670T1 (en) 1997-04-11 2002-10-15 Searle & Co ANTAGONISTIC ANTI-AVB3 INTEGRIN ANTIBODIES
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (en) 1998-04-15 2002-01-15 Lexigen Pharm Corp Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor
AU758851B2 (en) * 1998-04-17 2003-04-03 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
US6284536B1 (en) * 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU770555B2 (en) * 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
HUP0103329A3 (en) 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
MXPA01011250A (en) 1999-05-06 2002-08-12 Univ Wake Forest Compositions and methods for identifying antigens which elicit an immune response.
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1210372B1 (en) * 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
EP1200479B1 (en) 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2001062298A2 (en) * 2000-02-24 2001-08-30 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20020019342A1 (en) 2000-05-12 2002-02-14 Robert Bayer In vitro modification of glycosylation patterns of recombinant glycopeptides
CN1270775C (en) 2000-06-29 2006-08-23 默克专利有限公司 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enbancing agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002057435A2 (en) * 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
KR100900176B1 (en) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2008502317A (en) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング IL-7 fusion protein
KR20060124656A (en) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP4937132B2 (en) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング IL-7 variants with reduced immunogenicity
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
SI1966238T1 (en) 2005-12-30 2012-08-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
EA016429B1 (en) 2005-12-30 2012-04-30 Мерк Патент Гмбх Anti-cd19 antibodies with reduced immunogenicity
AU2006332216A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6Ralpha to gp130
PL1999154T3 (en) 2006-03-24 2013-03-29 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009542592A (en) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Compositions and methods for enhancing the effectiveness of an IL-2-mediated immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004329A1 (en) * 1989-09-20 1991-04-04 Abbott Laboratories Method of producing fusion proteins
WO1991013166A1 (en) * 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
WO1999043713A1 (en) * 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILLIES ET AL.: "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors", CANCER RESEARCH, vol. 59, 1 May 1999 (1999-05-01), pages 2159 - 2166, XP002107035 *
STEVENSON ET AL.: "Conjugation of human Fcgamma in closed-hinge or open-hinge configuration to Fab' gamma and analogous ligands", J. OF IMMUNOLOGY, vol. 158, 1997, pages 2242 - 2250, XP002955118 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site

Also Published As

Publication number Publication date
HUP0303428A2 (en) 2004-01-28
BR0207854A (en) 2004-08-24
PL366981A1 (en) 2005-02-07
CA2440221C (en) 2013-02-05
ZA200307792B (en) 2004-07-06
PT1366067E (en) 2012-11-29
JP4234438B2 (en) 2009-03-04
AU2002248571B2 (en) 2007-01-18
PL206701B1 (en) 2010-09-30
JP2004525630A (en) 2004-08-26
KR100900176B1 (en) 2009-06-02
CA2440221A1 (en) 2002-09-19
DK1366067T3 (en) 2012-10-22
US7148321B2 (en) 2006-12-12
CN1509293A (en) 2004-06-30
EP1366067B1 (en) 2012-09-26
KR20030092015A (en) 2003-12-03
WO2002072605A2 (en) 2002-09-19
MXPA03008031A (en) 2003-12-04
US20030044423A1 (en) 2003-03-06
US8066994B2 (en) 2011-11-29
ES2393733T3 (en) 2012-12-27
KR20090010127A (en) 2009-01-28
US20060263856A1 (en) 2006-11-23
CN1330664C (en) 2007-08-08
EP1366067A4 (en) 2005-07-20
EP1366067A2 (en) 2003-12-03
RU2003129528A (en) 2005-04-10

Similar Documents

Publication Publication Date Title
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
EP2502935A3 (en) Improved antibodies having altered effector function and methods for making the same
WO2003052082A3 (en) Fusion partner cells and uses thereof
WO2000023564A3 (en) Protein design automation for protein libraries
AU2002235994A1 (en) Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2003014325A3 (en) Protein design automation for protein libraries
WO2002103024A3 (en) Stabilized proteins with engineered disulfide bonds
WO2003027003A3 (en) Methods of nanotube films and articles
WO2002085923A3 (en) In vivo incorporation of unnatural amino acids
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2004024993A8 (en) Magnetically modified electrodes as well as methods of making and using the same
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
AU2002311756A1 (en) Sequence specific recombinase-based methods for producing intron containing vectors and compositions for use in practicing the same
EP1288931A3 (en) Optical recording article
WO2004011605A3 (en) Hybrid protein methods and compositions
WO2002036627A3 (en) Interferons, uses and compositions related thereto
AU2002256347A1 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
WO2002049625A3 (en) Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
WO2002068453A3 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002717581

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002248571

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008031

Country of ref document: MX

Ref document number: 2440221

Country of ref document: CA

Ref document number: 028060644

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020037011719

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002571518

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/07792

Country of ref document: ZA

Ref document number: 200307792

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002717581

Country of ref document: EP

Ref document number: 1020037011719

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642